-transparent.png){kind=logo}
Certain flavonoids having a C-2,3-double bond were reported to show an inhibitory activity against T-lymphocyte proliferation, but not against B-lymphocyte proliferation in vitro. In the course of these studies, vitexicarpin (3',5-dihydroxy-3,4',6,7-tetramethoxyflavone) isolated from the fruits of Vitex rotundifolia was found to show potent inhibition against lymphocyte proliferation. Vitexicarpin inhibited T-lymphocyte proliferation as well as B-lymphocyte proliferation at > 0.1 microM. IC50's were approximately 0.7 microM both for T- and B-cell proliferation. The inhibitory activity of vitexicarpin was reversible. Vitexicarpin also inhibited the growth of certain cancer cell lines, EL-4 and P815.9 (IC50 = 0.25-0.3 microM). These results suggest that vitexicarpin may be a potential therapeutic agent involved in inflammatory/immunoregulatory disorders such as rheumatoid arthritis and lymphomas.
K M You, and
K H Son, and
H W Chang, and
S S Kang, and
H P Kim
December 2010,
Acta pharmacologica Sinica,
K M You, and
K H Son, and
H W Chang, and
S S Kang, and
H P Kim
November 1999,
Journal of natural products,
K M You, and
K H Son, and
H W Chang, and
S S Kang, and
H P Kim
November 2017,
Natural product research,
K M You, and
K H Son, and
H W Chang, and
S S Kang, and
H P Kim
November 2013,
Bioorganic & medicinal chemistry letters,
K M You, and
K H Son, and
H W Chang, and
S S Kang, and
H P Kim
April 2002,
Journal of natural products,
K M You, and
K H Son, and
H W Chang, and
S S Kang, and
H P Kim
April 2012,
Inflammation,
K M You, and
K H Son, and
H W Chang, and
S S Kang, and
H P Kim
January 2005,
Yao xue xue bao = Acta pharmaceutica Sinica,
K M You, and
K H Son, and
H W Chang, and
S S Kang, and
H P Kim
June 2004,
The Journal of nutrition,
K M You, and
K H Son, and
H W Chang, and
S S Kang, and
H P Kim
November 2002,
Planta medica,
K M You, and
K H Son, and
H W Chang, and
S S Kang, and
H P Kim
January 2012,
Journal of biomedicine & biotechnology,
